eFFECTOR Therapeutics IPO

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).

Register for Details

For more details on financing and valuation for eFFECTOR Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about eFFECTOR Therapeutics

Forge green plus iconForge green minus icon

What is eFFECTOR Therapeutics's IPO price?

eFFECTOR Therapeutics's IPO price is $10.6 as of 1/18/24.
Forge green plus iconForge green minus icon

What is eFFECTOR Therapeutics's funding to date?

eFFECTOR Therapeutics has raised $152.08MM to date.
Forge green plus iconForge green minus icon

When was eFFECTOR Therapeutics founded?

eFFECTOR Therapeutics was founded in 2012.

eFFECTOR Therapeutics Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
8/24/2017 Series C $39.1MM raised $XXX.XX $XXX.XX
12/22/2015 Series B $56MM raised $XXX.XX $XXX.XX
5/20/2013 Series A $56.98MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: May 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.